公开(公告)号：EP1291343B1

公开(公告)日：2006-12-06

申请号：EP01941061.2

申请日：2001-06-15

申请人： TAISHO PHARMACEUTICAL CO., LTD

发明人： SATO, Masakazu ,  MIYATA, Noriyuki ,  ISHII, Takaaki ,  KOBAYASHI, Yuko ,  AMADA, Hideaki

IPC分类号： C07D213/74 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12 ,  C07D409/12 ,  C07D473/08 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/443 ,  A61K31/4436 ,  A61K31/4433 ,  A61K31/444 ,  A61K31/522 ,  A61P13/12 ,  A61P9/00 ,  A61P9/10

CPC分类号： C07D213/74

摘要： Pharmaceutical agents for inhibiting the production of 20-HETE which participates in constriction or dilation of microvessels in major organs such as the kidneys and the cerebral blood vessels, or participates in causing cell proliferation are provided. The present invention relates to hydroxyamidine compounds represented by the formula: wherein R represents a group represented by the formula: R -(CH2)m- (wherein R represents a C3-8 cycloalkyl group, a C2-6 alkoxycarbonyl group, a C2-10 alkenyl group, a C2-6 alkynyl group, a substituted or non-substituted aryl group, or the like, and m is an integer of 1 to 8), a group represented by the formula: R -A- (wherein R represents a hydrogen atom, a C1-6 alkoxy group, a C3-8 cycloalkoxy group, or the like, and A represents a straight-chain C2-10 alkylene group which may be substituted with a C1-6 alkyl group or a trifluoromethyl group), or a C3-8 cycloalkyl group, and X represents an oxygen atom or a sulfur atom, or pharmaceutically acceptable salts thereof, and relates to medicines including the same as active ingredients.

公开(公告)号：EP1291343A1

公开(公告)日：2003-03-12

申请号：EP01941061.2

申请日：2001-06-15

申请人： TAISHO PHARMACEUTICAL CO., LTD

发明人： SATO, Masakazu ,  MIYATA, Noriyuki ,  ISHII, Takaaki ,  KOBAYASHI, Yuko ,  AMADA, Hideaki

IPC分类号： C07D213/74 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12 ,  C07D409/12 ,  C07D473/08 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/443 ,  A61K31/4436 ,  A61K31/4433 ,  A61K31/444 ,  A61K31/522 ,  A61P13/12 ,  A61P9/00 ,  A61P9/10

CPC分类号： C07D213/74

摘要： Pharmaceutical agents for inhibiting the production of 20-HETE which participates in constriction or dilation of microvessels in major organs such as the kidneys and the cerebral blood vessels, or participates in causing cell proliferation are provided. The present invention relates to hydroxyamidine compounds represented by the formula:
wherein R 1 represents a group represented by the formula: R 2 -(CH 2 ) m - (wherein R 2 represents a C 3-8 cycloalkyl group, a C 2-6 alkoxycarbonyl group, a C 2-10 alkenyl group, a C 2-6 alkynyl group, a substituted or non-substituted aryl group, or the like, and m is an integer of 1 to 8), a group represented by the formula: R 3 -A- (wherein R 3 represents a hydrogen atom, a C 1-6 alkoxy group, a C 3-8 cycloalkoxy group, or the like, and A represents a straight-chain C 2-10 alkylene group which may be substituted with a C 1-6 alkyl group or a trifluoromethyl group), or a C 3-8 cycloalkyl group, and X represents an oxygen atom or a sulfur atom,
or pharmaceutically acceptable salts thereof, and relates to medicines including the same as active ingredients.

摘要翻译： 提供了用于抑制参与诸如肾脏和脑血管等主要器官的微血管收缩或扩张的20-HETE的生产的药剂，或参与引起细胞增殖。 本发明涉及由下式表示的羟基脒化合物：其中R 1表示由下式表示的基团：R 2 - （CH 2）m - （其中R 2表示C 3-8环烷基 基团，C 2-6烷氧基羰基，C 2-10烯基，C 2-6炔基，取代或未取代的芳基等，m为1〜8的整数）表示的基团 通式为R 3 -A（其中R 3表示氢原子，C 1-6烷氧基，C 3-8环烷氧基等，A表示直链C 2-10 可以被C 1-6烷基或三氟甲基取代的亚烷基）或C 3-8环烷基，X表示氧原子或硫原子，或其药学上可接受的盐，涉及包括 与活性成分一样。